Product Sales
Full Year 2019 Product Sales
See 2019 net sales of our top 20 Innovative Medicines products in the table below.
| Brands | Net Sales (USD m) | % change (USD) | Business Franchise |
|---|---|---|---|
| Cosentyx | 3,551 | 25% | Immunology, Hepatology and Dermatology |
| Gilenya | 3,223 | -4% | Neuroscience |
| Lucentis | 2,086 | 2% | Ophthalmology |
| Tasigna | 1,880 | 0% | Oncology |
| Entresto | 1,726 | 68% | Cardiovascular, Renal and Metabolism |
| Sandostatin | 1,585 | 0% | Oncology |
| Afinitor/Votubia | 1,539 | -1% | Oncology |
| Promacta/Revolade | 1,416 | 21% | Oncology |
| Tafinlar + Mekinist | 1,338 | 16% | Oncology |
| Galvus Group | 1,297 | 1% | Established Medicines |
| Gleevec/Glivec | 1,263 | -19% | Oncology |
| Xolair | 1,173 | 13% | Respiratory |
| Jakavi | 1,114 | 14% | Oncology |
| Diovan Group | 1,064 | 4% | Established Medicines |
| Exforge Group | 1,025 | 2% | Established Medicines |
| Exjade/Jadenu | 975 | -11% | Oncology |
| Votrient | 755 | -9% | Oncology |
| Ilaris | 671 | 21% | Immunology, Hepatology and Dermatology |
| Zortress/Certican | 485 | 5% | Established Medicines |
| Kisqali | 480 | 104% | Oncology |